Population Assessment of Tobacco and Health (PATH) Study [United States] Biomarker Restricted-Use Files / United States Department of Health and Human Services. National Institutes of Health. National Institute on Drug Abuse, United States Department of Health and Human Services. Food and Drug Administration. Center for Tobacco Products.

Format:

Datafile

Contributor:

United States Department of Health and Human Services. National Institutes of Health. National Institute on Drug Abuse.

United States Department of Health and Human Services. Food and Drug Administration. Center for Tobacco Products.

Inter-university Consortium for Political and Social Research.

Series:

ICPSR (Series) ; 36840.

ICPSR ; 36840

Population Assessment of Tobacco and Health (PATH) Study Series

Language:

English

Physical Description:

1 online resource.

Edition:

2018-05-01.

Place of Publication:

Ann Arbor, Mich. : Inter-university Consortium for Political and Social Research [distributor], 2017.

System Details:

Mode of access: Intranet.

data file

Summary:

The Population Assessment of Tobacco and Health (PATH) Study is a collaboration between the National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), and the Center for Tobacco Products (CTP), Food and Drug Administration (FDA). The study was launched in 2011 to inform the FDA's tobacco regulatory activities under the (http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm246129.htm)Family Smoking Prevention and Tobacco Control Act (TCA). For Wave 1 (baseline), the PATH Study sampled over 150,000 mailing addresses across the United States to create a national sample of tobacco users and non-users, yielding interviews with 45,971 adult and youth respondents. Each adult respondent, who completed the interview, was asked to provide up to three biospecimens. Providing biospecimens was voluntary and was not a condition of participation. Respondents were asked to report their use of all nicotine-containing products during the 3-day period prior to the time of any biospecimen collection (Nicotine Exposure Questions (NEQs)) to facilitate interpretation of biomarker results. Of the 32,320 respondents who completed the adult interview, 21,801 (67.4 percent) provided a urine specimen and 14,520 (44.9 percent) provided a blood specimen. A sample of 11,522 adults who provided sufficient urine for the planned analyses were selected from a diverse mix of six tobacco product use groups representing never, current, and recent former (within 12 months) users of tobacco products. 7,159 of the 11,522 adults also provided a blood specimen. All urine and blood specimens provided by these sampled adults were sent for laboratory analysis. Restricted-Use Biomarker Data Files (Biomarker RUF) consist of three different types of files: <list type="bulleted) <itm>2 Collection and NEQs for Urine (DS1001) and Blood (DS1101)</itm> <itm>2 Biomarker Weight files including variables for use in variance estimation for Urine (DS1002) and Blood (DS1102)</itm> <itm>7 Urine Panels (DS1003 to DS1009) and 1 Serum Panel (DS1103) containing biomarker assay results</itm> </list> References to the collection of biospecimens will be specified by the collected specimen, i.e., urine and (whole) blood. However, references to biomarker analyses and analytes will be specified by the type of matrix (serum, plasma, or urine) used for the analysis.Cf: http://doi.org/10.3886/ICPSR36840.v2

Contents:

Master Linkage File

Wave 1: Urine Collection and NEQ Data

Wave 1: Urine Biomarker Weights

Wave 1: Urine Panel - Speciated Arsenic (AsSpec)

Wave 1: Urine Panel - Enzymatic Urinary Creatinine (CREAU)

Wave 1: Urine Panel - Metals (Metals)

Wave 1: Urine Panel - Hydroxy Polycyclic Aromatic Hydrocarbons (PAH)

Wave 1: Urine Panel - Tobacco-Specific Nitrosamines (TSNA)

Wave 1: Urine Panel - Urinary Nicotine Metabolites (Cotinine and Hydroxycotinine) (UNICM)

Wave 1: Urine Panel - Volatile Organic Compounds Metabolites (VOCM)

Wave 1: Blood Collection and NEQ Data

Wave 1: Blood Biomarker Weights

Wave 1: Serum Panel - Cotinine and Hydroxycotinine (SCOT)

Notes:

Title from ICPSR DDI metadata of 2018-06-14.

Access Restriction:

Restricted for use by site license.